Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Review Approval Letter - Bivigam


Our STN: 125389/0                                                                          
Biotest Pharmaceuticals Corporation
Attention: Matthew Vaughn
5800 Park of Commerce Blvd. NW
Boca Raton, FL  33487
Dear Mr. Vaughn:
We have reviewed your submission to your biologics license application (BLA) for Immune Globulin Intravenous (Human), dated January 14, 2011, requesting a proprietary name review. 
In consultation with CBER’s Advertising and Promotional Labeling Branch (APLB) we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, Bivigam, is acceptable at this time.
If you have any questions, please contact Pratibha Rana at (301) 827-6124.
Sincerely yours,
Basil Golding, M.D.
Division of Hematology
Office of Blood Research and Review
Center for Biologics
  Evaluation and Research

Page Last Updated: 01/18/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English